| Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET K Baete, J Nuyts, K Van Laere, W Van Paesschen, S Ceyssens, ... Neuroimage 23 (1), 305-317, 2004 | 140 | 2004 |
| Glycine and glycine receptor signalling in non-neuronal cells J Van den Eynden, S SahebAli, N Horwood, S Carmans, B Brône, ... Frontiers in Molecular Neuroscience 2, 799, 2009 | 98 | 2009 |
| Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature NJ Fredriksson, K Elliott, S Filges, J Van den Eynden, A Ståhlberg, ... PLoS genetics 13 (5), e1006773, 2017 | 75 | 2017 |
| Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers K Elliott, M Boström, S Filges, M Lindberg, J Van den Eynden, A Ståhlberg, ... PLoS genetics 14 (12), e1007849, 2018 | 72 | 2018 |
| Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1 K Van Laere, L De Ceuninck, R Dom, J Van den Eynden, H Vanbilloen, ... European journal of nuclear medicine and molecular imaging 31, 1119-1127, 2004 | 68 | 2004 |
| Lack of detectable neoantigen depletion signals in the untreated cancer genome J Van den Eynden, A Jiménez-Sánchez, ML Miller, E Larsson Nature genetics 51 (12), 1741-1748, 2019 | 62 | 2019 |
| Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib J Guan, S Fransson, JT Siaw, D Treis, J Van den Eynden, D Chand, ... Molecular Case Studies 4 (4), a002550, 2018 | 58 | 2018 |
| Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events A Ashouri, VI Sayin, J Van den Eynden, SX Singh, T Papagiannakopoulos, ... Nature communications 7 (1), 13197, 2016 | 57 | 2016 |
| Dorsal Unpaired Median Neurons of Locusta migratoria Express Ivermectin- and Fipronil-Sensitive Glutamate-Gated Chloride Channels D Janssen, C Derst, R Buckinx, J Van den Eynden, JM Rigo, ... Journal of neurophysiology 97 (4), 2642-2650, 2007 | 55 | 2007 |
| The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters S Carmans, JJA Hendriks, K Thewissen, J Van den Eynden, P Stinissen, ... Journal of neuroscience research 88 (11), 2420-2430, 2010 | 49 | 2010 |
| Targeting filamin A reduces macrophage activity and atherosclerosis S Bandaru, C Ala, R Salimi, MK Akula, M Ekstrand, S Devarakonda, ... Circulation 140 (1), 67-79, 2019 | 48 | 2019 |
| SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering J Van den Eynden, AC Fierro, LPC Verbeke, K Marchal BMC bioinformatics 16, 1-12, 2015 | 48 | 2015 |
| ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation M Borenäs, G Umapathy, WY Lai, DE Lind, B Witek, J Guan, ... The EMBO journal 40 (3), e105784, 2021 | 44 | 2021 |
| Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways J Van den Eynden, G Umapathy, A Ashouri, D Cervantes-Madrid, ... Science signaling 11 (557), eaar5680, 2018 | 42 | 2018 |
| Mutational signatures are critical for proper estimation of purifying selection pressures in cancer somatic mutation data when using the dN/dS metric J Van den Eynden, E Larsson Frontiers in Genetics 8, 259796, 2017 | 40 | 2017 |
| Simultaneous discovery of cancer subtypes and subtype features by molecular data integration T Le Van, M Van Leeuwen, A Carolina Fierro, D De Maeyer, ... Bioinformatics 32 (17), i445-i454, 2016 | 38 | 2016 |
| Pathway relevance ranking for tumor samples through network-based data integration LPC Verbeke, J Van den Eynden, AC Fierro, P Demeester, J Fostier, ... PloS one 10 (7), e0133503, 2015 | 37 | 2015 |
| 11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma JT Siaw, N Javanmardi, J Van den Eynden, DE Lind, S Fransson, ... Cell reports 32 (12), 2020 | 34 | 2020 |
| Somatic mutation patterns in hemizygous genomic regions unveil purifying selection during tumor evolution J Van den Eynden, S Basu, E Larsson PLoS genetics 12 (12), e1006506, 2016 | 33 | 2016 |
| ATR inhibition enables complete tumour regression in ALK-driven NB mouse models J Szydzik, DE Lind, B Arefin, Y Kurhe, G Umapathy, JT Siaw, A Claeys, ... Nature communications 12 (1), 6813, 2021 | 29 | 2021 |
